Immune-Modulating effects of early postoperative elemene combined with S-1 chemotherapy in patients with advanced gastric cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062109

Enrollment

Unknown

Registered

2022-07-22

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

S-1:S-1 chemotherapy

elemene combined with S-1 :elemene combined with S-1 chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years, <= 80 years; 2. D2 radical gastrectomy; 3. postoperative pathological diagnosis of advanced gastric cancer; 4.patients whose survival period is expected to be more than 6 months; 5. informed this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Other malignant tumors in the past five years; 2.complicated with severe heart disease, such as symptomatic coronary heart disease, congestive heart failure of NYHA II or above, arrhythmia requiring drug intervention or history of myocardial infarction within 1 year; 3.pregnant or nursing women; 4.clinical judgment showed distant metastasis; having transplanted organs and requiring immunosuppressive therapy; allergic constitution; 5.with neurological or mental disorders; 6.there are other chemotherapy taboos.

Design outcomes

Primary

Measure	Time frame
Cellular immunologic parameters;	—

Secondary

Measure	Time frame
Inflammatory index;	—

Countries

China

Contacts

Public ContactKang Weiming

Peking Union Medical College Hospital

pumchkangweiming@126.com+86 13810979989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026